BESPARK Trademark

Trademark Overview


On Wednesday, March 19, 2025, a trademark application was filed for BESPARK with the United States Patent and Trademark Office. The USPTO has given the BESPARK trademark a serial number of 79433020. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, June 15, 2026. This trademark is owned by bespark bio GmbH. The BESPARK trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Scientific laboratory services; scientific analytical laboratory services; technology consultation in the field of artificial intelligence; research in the field of artificial intelligence technology; computer system analysis; design of computer-simulated models; computer software design for others; biochemistry services, namely, biochemical analysis services; medical research laboratories; chemistry services, namely, research and development services in the field of chemistry; chemical laboratories; chemical analysis; conducting technical project studies, namely, conducting feasibility studies in the field of new technologies; electronic data storage; provision of research services, namely, medical research services; biomedical research services; research relating to biotechnology, namely, biotechnology research; pharmaceutical research services; bacteriological research; chemical research; medical and pharmacological research services; research and development of new products for oth...

Viral vaccines; vaccines for human use; cells for medical use; antibodies for medical purposes; pharmaceutical preparations for use in oncology or the treatment of solid tumor oncological diseases; pharmaceutical preparations and substances for use in oncology for the treatment of solid tumor oncological diseases; biological preparations for medical purposes for the treatment of solid tumor oncological diseases; chemical preparations for medical purposes, namely, for the treatment of solid tumor oncological diseases; all the foregoing excluding preparations for the diagnosis or treatment of retinal degenerative disorders, hematologic disorders, and hematologic diseases
bespark

General Information


Serial Number79433020
Word MarkBESPARK
Filing DateWednesday, March 19, 2025
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateMonday, June 15, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 7, 2026

Trademark Statements


Goods and ServicesScientific laboratory services; scientific analytical laboratory services; technology consultation in the field of artificial intelligence; research in the field of artificial intelligence technology; computer system analysis; design of computer-simulated models; computer software design for others; biochemistry services, namely, biochemical analysis services; medical research laboratories; chemistry services, namely, research and development services in the field of chemistry; chemical laboratories; chemical analysis; conducting technical project studies, namely, conducting feasibility studies in the field of new technologies; electronic data storage; provision of research services, namely, medical research services; biomedical research services; research relating to biotechnology, namely, biotechnology research; pharmaceutical research services; bacteriological research; chemical research; medical and pharmacological research services; research and development of new products for others; scientific research and development services; pharmaceutical research and development; medical and scientific research, namely, conducting clinical trials for others; technology advisory services relating to gene therapy research; scientific research in the field of gene therapy; culturing of cells for others for scientific research purposes; research and development services relating to vaccines; research and development of vaccines and medicines; medical research; scientific research for medical purposes in the area of cancerous diseases; medical research in the field of oncology; platform as a service (PAAS) featuring computer software platforms for use in bioprocess data modeling, simulation of biopharmaceutical manufacturing processes, digital-twin modeling of cell-culture and biologics production processes, and analysis of bioprocess development data; software engineering services for data processing programs; technological consultancy services for digital transformation; technological consultancy, namely, computer technology consultancy; technological research relating to bioprocessing, biotechnology, cell-line development, process development, analytical development, product validation, biologics, biosimilars, viral vectors, vaccines, ATMPs, and bionanoparticles; chemical technological research, namely, technological research in the field of chemistry; consultancy services relating to technological research, namely, technology consultation and research in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; technical writing; scientific research; scientific and technological services, namely, computer aided scientific research services in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; scientific research and development; Scientific and technological services, namely, scientific research and analysis in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; scientific research in the field of genetics and genetic engineering; scientific research in the field of genetics; biological analysis; biochemical analysis services; scientific and technological services, namely, scientific analysis in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; consultancy in the field of scientific research, namely, scientific research consultancy; scientific and technological services, namely, scientific research, scientific analysis, scientific testing, and product validation for quality evaluation purposes in the field of biotechnology, bioprocessing, cell-line development, process development, analytical development, and biopharmaceutical product validation; testing of materials, authentication in the field of biopharmaceutical raw materials, biologics, biosimilars, viral vectors, vaccines, ATMPs, and bionanoparticles and quality control for others; research laboratory analysis services in the field of bacteriology; technical consultancy in the field of industrial research; computer programming services for the analysis of data; computer design and programming services, namely, computer programming and software design; analysis of product development, namely, product research and development; quality assurance consultancy, namely, consultancy related to quality assurance services in the field of biopharmaceutical manufacturing, bioprocessing, cell-culture processes, and biologics development; consultancy services relating to quality control, namely, Consultancy relating to inspection of food processing facilities for quality control purposes; computer aided scientific testing, namely, computer aided genetic testing for scientific research purposes; computer aided testing services, namely computer aided product safety testing; engineering testing, namely, testing of biopharmaceutical manufacturing equipment, bioreactor systems, cell-culture systems, and bioprocessing systems for scientific research and product-development purposes; conducting of quality control tests, namely, quality control testing for others; technical measuring, namely, technical measuring and testing of biopharmaceutical process parameters, namely, cell-culture performance, bioreactor process performance, product quality attributes, and analytical assay performance, all for quality assurance purposes; scientific testing services, namely, scientific testing of biopharmaceutical products, biologics, biosimilars, viral vectors, vaccines, ATMPs, bionanoparticles, cell cultures, and bioprocess materials; development and test of chemical production methods; development of measuring and testing methods, namely, development and establishment of testing specifications and procedures in the field of biopharmaceutical manufacturing, bioprocessing, cell-line development, process development, analytical development, and product validation for quality evaluation purposes; development of testing methods, namely, development and establishment of testing specifications and procedures in the field of biopharmaceutical manufacturing, bioprocessing, cell-line development, process development, analytical development, and product validation for quality evaluation purposes; design and testing for new product development; analysis and evaluation of product development, namely, product research and development evaluation for biopharmaceutical products, biologics, biosimilars, viral vectors, vaccines, ATMPs, and bionanoparticles for quality evaluation purposes; biological research laboratory services; product quality control testing, namely, quality control testing of products; product testing; product quality testing; process monitoring for quality assurance, namely, monitoring of biopharmaceutical manufacturing and bioprocessing processes for quality assurance purposes; quality assessment, namely, quality assessment services for biopharmaceutical products, biologics, biosimilars, viral vectors, vaccines, ATMPs, bionanoparticles, cell cultures, and bioprocess materials for quality evaluation purposes; quality control for others; inspection of pharmaceuticals; scientific risk assessment, namely, scientific risk assessment services for biopharmaceutical process development, analytical development, product validation, and bioprocess scale-up; scientific laboratory services relating to the production of monoclonal antibodies; research and development services in the field of antibodies; scientific research and development services in the field of antibody technology; cell culture services for scientific and research purposes, for others
Goods and ServicesViral vaccines; vaccines for human use; cells for medical use; antibodies for medical purposes; pharmaceutical preparations for use in oncology or the treatment of solid tumor oncological diseases; pharmaceutical preparations and substances for use in oncology for the treatment of solid tumor oncological diseases; biological preparations for medical purposes for the treatment of solid tumor oncological diseases; chemical preparations for medical purposes, namely, for the treatment of solid tumor oncological diseases; all the foregoing excluding preparations for the diagnosis or treatment of retinal degenerative disorders, hematologic disorders, and hematologic diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 18, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, September 18, 2025
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party Namebespark bio GmbH
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressAT

Trademark Events


Event DateEvent Description
Thursday, September 18, 2025SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Monday, September 22, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 22, 2025APPLICATION FILING RECEIPT MAILED
Tuesday, September 23, 2025ASSIGNED TO EXAMINER
Tuesday, November 11, 2025NON-FINAL ACTION WRITTEN
Wednesday, November 12, 2025NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, December 18, 2025NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Friday, December 19, 2025NON-FINAL ACTION WRITTEN
Saturday, December 20, 2025NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, January 23, 2026REFUSAL PROCESSED BY MPU
Friday, January 23, 2026NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, February 12, 2026REFUSAL PROCESSED BY IB
Wednesday, March 4, 2026ASSIGNED TO EXAMINER
Wednesday, June 3, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, June 3, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 3, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 5, 2026EXAMINERS AMENDMENT -WRITTEN
Friday, June 5, 2026EXAMINERS AMENDMENT E-MAILED
Friday, June 5, 2026EXAMINER'S AMENDMENT ENTERED
Friday, June 5, 2026APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, June 5, 2026NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, June 17, 2026NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, June 17, 2026NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB